Technology evaluation: HSPPC-96, antigenics.

Article Details

Citation
Copy to clipboard

Minev BR

Technology evaluation: HSPPC-96, antigenics.

Curr Opin Mol Ther. 2003 Dec;5(6):680-7.

PubMed ID
14755896 [ View in PubMed
]
Abstract

Antigenics is developing HSPPC-96, a vaccine based on heat shock protein for the potential treatment of various cancer indications. The compound is currently undergoing phase III clinical trials for renal cell carcinoma and melanoma.

DrugBank Data that Cites this Article

Drugs